AI Drug Developer Basecamp Hits $800 Million Valuation

AI-based drug developer Basecamp is now valued at $800 million after closing a $140 million funding round, The Economic Times reports.

The round marks one of the larger recent financing events for an artificial-intelligence drugmaker and pushes Basecamp's valuation close to unicorn territory. The company applies machine learning to drug development, a field that continues to attract capital despite a broader slowdown in biotech funding.

How large is the deal?

The numbers anchor the story:

• $140 million — the size of the funding round Basecamp has raised
• $800 million — the company's post-round valuation
• $200 million short — the gap between Basecamp's new worth and the billion-dollar "unicorn" threshold

The Economic Times, which first reported the financing, did not disclose the names of the investors participating in the round or the intended use of proceeds.

Why does AI drug development keep drawing capital?

Drug discovery has become one of the most cash-intensive applications of artificial intelligence. Startups in the sector use machine-learning models to identify promising drug candidates, predict how molecules will behave, and cut the early, highest-risk stages of pharmaceutical research.

That pitch has sustained investor appetite for the category even as funding for traditional biotech has tightened. A valuation of $800 million places Basecamp among the more richly valued private players in AI-driven medicine.

What comes next?

Crossing the $800 million mark puts Basecamp within striking distance of unicorn status. The company's next test will be converting its $140 million war chest into clinical progress — the milestone that ultimately determines whether AI drug discovery valuations hold up.